Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Milestone Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MIST
Nasdaq
8731
https://www.milestonepharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Milestone Pharmaceuticals Inc
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
- May 2nd, 2024 12:00 pm
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
- Apr 17th, 2024 12:00 pm
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
- Apr 8th, 2024 3:36 pm
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
- Apr 3rd, 2024 12:00 pm
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
- Apr 1st, 2024 12:00 pm
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
- Mar 28th, 2024 11:00 am
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
- Mar 21st, 2024 11:14 am
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
- Feb 29th, 2024 9:01 pm
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants
- Feb 29th, 2024 12:00 pm
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
- Feb 28th, 2024 9:37 pm
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT
- Feb 26th, 2024 12:00 pm
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround
- Jan 16th, 2024 2:35 pm
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
- Dec 27th, 2023 4:11 pm
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
- Dec 26th, 2023 12:00 pm
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) top owners are individual investors with 52% stake, while 34% is held by institutions
- Dec 26th, 2023 10:10 am
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
- Nov 21st, 2023 12:00 pm
Milestone Pharmaceuticals Third Quarter 2023 Earnings: US$0.45 loss per share (vs US$0.34 loss in 3Q 2022)
- Nov 15th, 2023 10:16 am
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
- Nov 13th, 2023 11:57 am
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023
- Nov 11th, 2023 3:00 pm
Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR
- Nov 7th, 2023 12:00 pm
Scroll